» Authors » Brian G Weinshenker

Brian G Weinshenker

Explore the profile of Brian G Weinshenker including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 217
Citations 14330
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Carnero Contentti E, Rojas J, Alonso R, Yeaman M, Weinshenker B
Front Immunol . 2024 Dec; 15:1515481. PMID: 39735550
Background: We evaluated comprehension and application of the 2015 neuromyelitis optica spectrum disorder (NMOSD) criteria core elements by neurologists in Latin America (LATAM) who routinely diagnose and care for NMOSD...
2.
Dinoto A, Cacciaguerra L, Krecke K, Chen J, Wingerchuk D, Weinshenker B, et al.
Neurol Neuroimmunol Neuroinflamm . 2024 Dec; 12(1):e200344. PMID: 39661938
Objectives: To characterize the frequency and clinicoradiologic phenotype of cerebellar involvement in attacks of aquaporin-4-IgG positive neuromyelitis optica spectrum disorder (AQP4+NMOSD) which are incompletely captured in current diagnostic criteria. Methods:...
3.
Hoffman E, Brown L, Jolliffe E, Sechi E, Harmsen W, Schilaty N, et al.
Mult Scler . 2024 Nov; 30(14):1830-1834. PMID: 39503327
Background: Rapidly reversible weakness with neck flexion (McArdle sign) is common in patients with multiple sclerosis (MS). The pathophysiology is unknown. Objective: To evaluate changes in central motor conduction time...
4.
Adnan R, Roikjaer S, Samadzadeh S, Richter C, Weinshenker B, Paul F, et al.
Front Neurol . 2024 Oct; 15:1449519. PMID: 39474367
Introduction: Physical exercise (PE) improves symptoms and quality of life in people with multiple sclerosis (pwMS). However, incorporating PE into daily lives of pwMS pose difficulties. As an alternative to...
5.
Hardy T, Weinshenker B
Mult Scler . 2024 Sep; 30(14):1838-1839. PMID: 39245943
No abstract available.
6.
Nathoo N, Neyal N, Atkinson E, Weinshenker B, Tillema J, Keegan B, et al.
Mult Scler Relat Disord . 2024 Aug; 90:105842. PMID: 39213863
Background: Differences in the MS course between White and Black populations is well accepted. The existence of a large Somali immigrant population in Minnesota facilitates a study of MS characteristics...
7.
Samadzadeh S, Adnan R, Berglova P, Barzegar M, Debrabant B, Roikjaer S, et al.
Front Immunol . 2024 Jul; 15:1380025. PMID: 39021565
Comorbidities in patients with multiple sclerosis (MS) and antibody-mediated diseases of the central nervous system (CNS) including neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein (MOG)-antibody-associated disease (MOGAD) are...
8.
Arnett S, Chew S, Leitner U, Hor J, Paul F, Yeaman M, et al.
J Neurol . 2024 Jul; 271(8):4794-4812. PMID: 38958756
Background: Aquaporin-4 (AQP4) antibody-associated neuromyelitis optica spectrum disorder (NMOSD) is an antibody-mediated inflammatory disease of the central nervous system. We have undertaken a systematic review and meta-analysis to ascertain the...
9.
Cree B, Kim H, Weinshenker B, Pittock S, Wingerchuk D, Fujihara K, et al.
Lancet Neurol . 2024 May; 23(6):588-602. PMID: 38760098
Background: Inebilizumab, an anti-CD19 B-cell-depleting antibody, demonstrated safety and efficacy in neuromyelitis optica spectrum disorder in the randomised controlled period of the N-MOmentum trial. Here, end-of-study data, including the randomised...
10.
Keegan B, Messina S, Hanson D, Holmes D, Camp J, Sechi E, et al.
AJNR Am J Neuroradiol . 2024 May; 45(7):943-950. PMID: 38754997
Background And Purpose: Progressive MS is typically heralded by a myelopathic pattern of asymmetric progressive motor weakness. Focal individual "critical" demyelinating spinal cord lesions anatomically associated with progressive motor impairment...